Literature DB >> 23493006

Tuberculosis with malaria or HIV co-infection in a large hospital in Luanda, Angola.

Emília Valadas1, Augusto Gomes, Ana Sutre, Sara Brilha, Afonso Wete, Thomas Hänscheid, Francisco Antunes.   

Abstract

INTRODUCTION: Three major public health problems, tuberculosis, malaria and HIV/AIDS, are widespread in Angola, often as co-infections in the same individual. In 2009, it was assumed that 44,151 new cases of TB occurred in Angola. Interestingly, interventions such as treatment/prevention of malaria appear to reduce mortality in HIV-infected and possibly TB co-infected patients. However, despite the seriousness of the situation, current data on TB and co-infection rates are scarce. This study aimed to characterize all TB cases seen at the Hospital Sanatório de Luanda, and to determine the co-infection rate with HIV and/or malaria.
METHODOLOGY: This retrospective study collected demographic, diagnostic and clinical data from all patients admitted during 2007.
RESULTS: A total of 4,666 patients were admitted, of whom 1,906 (40.8%) were diagnosed with TB. Overall, 1,111 patients (58.3%) were male and most patients (n=1302, 68.3%) were adults (≥ 14 years). The rate of HIV co-infection was 37.4% (n=712). Malaria was diagnosed during admission and hospital stay in 714 patients (37.5%), with Plasmodium falciparum the predominant species. Overall mortality was 15.2% (n=290).
CONCLUSIONS: Because Luanda does not have the infrastructure to perform culture-based diagnosis of TB, confirmation of TB is problematic. The HIV-co-infection rate is high, with 37.4% of patients requiring integrated approaches to address this problem. With more than 1/3 of the TB patients co-infected with malaria, even during the hospital stay, the prevention of malaria in TB patients appears to be an effective way to reduce overall mortality.

Entities:  

Mesh:

Year:  2013        PMID: 23493006     DOI: 10.3855/jidc.2703

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  7 in total

1.  Carboxymefloquine, the major metabolite of the antimalarial drug mefloquine, induces drug-metabolizing enzyme and transporter expression by activation of pregnane X receptor.

Authors:  Rita Piedade; Stefanie Traub; Andreas Bitter; Andreas K Nüssler; José P Gil; Matthias Schwab; Oliver Burk
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

Review 2.  Tuberculosis Comorbidity with Communicable and Noncommunicable Diseases.

Authors:  Matthew Bates; Ben J Marais; Alimuddin Zumla
Journal:  Cold Spring Harb Perspect Med       Date:  2015-02-06       Impact factor: 6.915

Review 3.  Recent Advances in Host-Directed Therapies for Tuberculosis and Malaria.

Authors:  Kely C Matteucci; André A S Correa; Diego L Costa
Journal:  Front Cell Infect Microbiol       Date:  2022-05-20       Impact factor: 6.073

4.  Pulmonary influenza A virus infection leads to suppression of the innate immune response to dermal injury.

Authors:  Meredith J Crane; Yun Xu; William L Henry; Sean P Gillis; Jorge E Albina; Amanda M Jamieson
Journal:  PLoS Pathog       Date:  2018-08-23       Impact factor: 6.823

5.  Prevalence of Malaria and TB Coinfection at a National Tuberculosis Treatment Centre in Uganda.

Authors:  Joseph Baruch Baluku; Sylvia Nassozi; Brian Gyagenda; Margret Namanda; Irene Andia-Biraro; William Worodria; Pauline Byakika-Kibwika
Journal:  J Trop Med       Date:  2019-07-25

Review 6.  Examining the Complex Relationship Between Tuberculosis and Other Infectious Diseases in Children.

Authors:  Elizabeth Whittaker; Elisa López-Varela; Claire Broderick; James A Seddon
Journal:  Front Pediatr       Date:  2019-06-25       Impact factor: 3.418

7.  Case Report: Three's a crowd: a case report examining the diagnostic and pharmacokinetic challenges in HIV-tuberculous meningitis-malaria co-infection.

Authors:  Jayne Ellis; Prosperity C Eneh; Kenneth Ssebambulidde; Morris K Rutakingirwa; Mohammed Lamorde; Joshua Rhein; Fiona V Cresswell; David R Boulware; Melanie R Nicol
Journal:  Wellcome Open Res       Date:  2019-01-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.